Title of article
Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial Original Research Article
Author/Authors
Mario Togni، نويسنده , , Stéphanie Eber، نويسنده , , Jeannette Widmer، نويسنده , , Michael Billinger، نويسنده , , Peter Wenaweser، نويسنده , , Stephane Cook، نويسنده , , Rolf Vogel، نويسنده , , Christian Seiler*، نويسنده , , Franz R. Eberli، نويسنده , , Willibald Maier، نويسنده , , Roberto Corti، نويسنده , , Marco Roffi، نويسنده , , Thomas F. Lüscher، نويسنده , , Ali Garachemani، نويسنده , , Otto M. Hess، نويسنده , , Simon Wandel ، نويسنده , , Bernhard Meier*، نويسنده , , Peter Jüni ، نويسنده , , Stephan Windecker*، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2007
Pages
9
From page
1123
To page
1131
Abstract
Objectives
We assessed the impact of vessel size on angiographic and long-term clinical outcome after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) within a randomized trial (SIRTAX [Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for Coronary Revascularization]).
Background
Percutaneous coronary intervention in small-vessel disease is associated with an increased risk of major adverse cardiac events (MACE).
Methods
A total of 1,012 patients were randomly assigned to treatment with SES (n = 503) or PES (n = 509). A stratified analysis of angiographic and clinical outcome was performed up to 2 years after PCI according to size of the treated vessel (reference vessel diameter ≤2.75 vs. >2.75 mm).
Results
Of 1,012 patients, 370 patients (37%) with 495 lesions underwent stent implantation in small vessels only, 504 patients (50%) with 613 lesions in large vessels only, and 138 patients (14%) with 301 lesions in both small and large vessels (mixed). In patients with small-vessel stents, SES reduced MACE by 55% (10.4% vs. 21.4%; p = 0.004), mainly driven by a 69% reduction of target lesion revascularization (TLR) (6.0% vs. 17.7%; p = 0.001) compared with PES at 2 years. In patients with large- and mixed-vessel stents, rates of MACE (large: 10.4% vs. 13.1%; p = 0.33; mixed: 16.7% vs. 18.0%; p = 0.83) and TLR (large: 6.9% vs. 8.6%; p = 0.47; mixed: 16.7% vs. 15.4%; p = 0.86) were similar for SES and PES. There were no significant differences with respect to death and myocardial infarction between the 3 groups.
Conclusions
Compared with PES, SES more effectively reduced MACE and TLR in small-vessel disease. Differences between SES and PES appear less pronounced in patients with large- and mixed-vessel disease. (The SIRTAX trial; http://clinicaltrials.gov/ct/show/NCT00297661?order=1; NCT00297661).
Keywords
PCI , TLR , mace , SES , PES , Percutaneous coronary intervention , DES , drug-eluting stent(s) , major adverse cardiac events , target lesion revascularization , sirolimus-eluting stent(s) , RVD , reference vessel diameter , paclitaxel-eluting stent(s)
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2007
Journal title
JACC (Journal of the American College of Cardiology)
Record number
472785
Link To Document